To STUDY THE DYNAMICS OF SERUM LEVELS OF VASCULAR REMODELING IN PATIENTS WITH HYPERTENSION, INCLUDING IN COMBINATION WITH TYPE 2 DIABETES MELLITUS DURING 12-MONTH THERAPY WITH PERINDOPRIL A

Aim To study the dynamics of serum markers for vascular remodeling in patients with arterial hypertension (AH), including AH associated with type 2 diabetes mellitus (DM2) during the 12-month treatment with the angiotensin-converting enzyme (ACE) inhibitor, perindopril A. Material and methods The study included patients with grade 1-2 AH with or without type 2 DM (30 and 32, respectively). Perindopril A 10 mg/day was administered for the outpatient correction of previous, ineffective antihypertensive therapy The following biomarkers were measured for all patients at baseline and at 12 months: matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), E-selectin, endothelin 1, transforming growth factor beta-1 (TGF-beta 1), and von Vilillebrand factor (WF). Laboratory tests were performed with enzyme immunoassay. Results After 12 months of the perindopril A (perindopril arginine) 10 mg/day treatment, both groups achieved the goal blood pressure. Evaluation of biomarker dynamics during the perindopril A treatment showed significant decreases in MMP-9, TIMP-1, and endothelin 1 in the AH group; then the level of TIMP-1 returned to normal values (p<0.05). In the AH+DM2 group, the MMP-9 concentration was significantly decreased (p<0.05); the other values did not show any significant differences. In both groups, MMP-9 was significantly decreased (28.6% (p=0.01) in group 1 and 33.2% (p=0.00) in group 2. Notably, in none of these groups, did this index reach normal values. Also, there were no significant differences in this index between the groups (p=0.66). It should be noted that the decreases in TIMP-1 were significantly different between the groups (p=0.001). Thus, this biomarker did not significantly decrease in patients with AH and DM2 (p=0.26) whereas in group 1 (AH without DM2), the level of TIMP-1 decreased by 39.3% and reached the normal range (p=0.005). Conclusion Concentrations of biomarkers were decreased in both groups. However, in the AH group, there were statistically significant decreases in the markers that reflect processes of fibrosis and vasoconstriction. At the same time in the AH+DM2 group, there was no significant dynamics of the biomarkers, which was most likely due to more pronounced damage of blood vessels. However, the decrease in MMP-9 may indicate an alleviation of fibrotic processes in arterial walls. These results allow a conclusion that the long-term treatment with the ACE inhibitor, perindopril A, may reverse remodeling of the vascular changes that are called "early vascular ageing".